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ABSTRACT
Peptide chloromethyl esters are important compounds in prodrug
synthesis. A simple, mild and efficient method for the synthesis of
chloromethyl esters of N-blocked amino acids and dipeptides using
exclusively bromochloromethane is reported. These N-blocked
amino acid and dipeptide chloromethyl esters react readily with the
carboxylic acid group of aspirin and with the sulfonamido group of
the antimalarial sulfamethazine, to give the corresponding prodrugs.
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RESEARCH REPORT
The search for suitable prodrugs as chemical drug delivery systems
is a high-priority task to overcome serious problems related to drug
solubility, oral absorption, toxicity and metabolic inactivation.[1,2]
Amino acids are promising carriers in prodrug design, as they can
improve water solubility and, thus, oral absorption of the drug.[3]
Dipeptides have also received attention as potential drug carriers to
improve oral absorption, targeted to the dipeptide transporters present
in the gastrointestinal tract. In this context, peptide chloromethyl esters
are suitable coupling agents, capable of reacting with several nucleophilic
groups frequently found in drugs,[4–6] such as the carboxylic acid
functionality.
In 1979, Wheeler and co-workers described the synthesis of
N-blocked amino acid chloromethyl esters [1] using triethylamine and
chloroiodomethane (Fig. 1).[7] However, they obtained rather low
global yields (9–25%) of [1], and had to face the difficulties of separating
the desired ester from large amounts of the gem-diester [2], also formed as
a by-product.[7] Recent work from Tsujihara’s group describes an
alternative synthetic route to N-blocked amino acid chloromethyl esters
[1] using the reagent chloromethyl chlorosulfate, with good to excellent
yields (79–100%).[8] Even though chloromethyl chlorosulfate is an
excellent reagent for this reaction step, its synthesis occurs in modest
yields (ca. 30%) and involves hazardous reagents (chlorosulfonic acid)
and products.[9]
We now wish to report an alternative method for the synthesis of
N-blocked amino acid chloromethyl esters [4], based on the reaction
between the corresponding N-blocked amino acid caesium salts [3] and
bromochloromethane (Fig. 2 and Table 1). Moreover, we have success-
fully extended this method to the synthesis of N-blocked dipeptide
Figure 1. Synthetic route to chloromethyl esters by Wheeler and co-workers.[7]
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chloromethyl esters [5] (Table 1). To our best knowledge, this is the first
report on the synthesis of N-blocked dipeptide chloromethyl esters.
The method now described involves the previous preparation of the
caesium salts of the N-protected amino acids and dipeptides, which were
formed quantitatively from the corresponding N-protected amino acids
and peptides. The use of caesium salts is known to improve the esterifica-
tion rates and yields of amino acid chloromethylation when comparedwith
the corresponding potassium, sodium, calcium or quaternary ammonium
salts.[10,11] The overall yields of [4] and [5] herein described range from
50 to 74% (Table 1), representing a significant improvement over the
previous method using chloroiodomethane as the chloromethylating
agent.[7] The formation of the gem-diester [2] was almost completely
suppressed, and thus it was easily separated from [4] or [5] by column
chromatography.
The applicability of chloromethyl esters [4] and [5] in prodrug
synthesis was assessed by preparing sulfamethazine and aspirin deriva-
tives (Fig. 2). Chloromethyl esters [4] and [5] react readily both with the
carboxylic acid group of aspirin and the sulfonamido group of the
antimalarial sulfamethazine, to give the corresponding prodrugs with
quite reasonable yields (ca. 40%, Table 2). Interestingly, no cyclization
of the N-blocked dipeptide chloromethyl esters [5] was observed in the
presence of the weak base sulfamethazine.
Figure 2. Synthetic route to potential sulfamethazine and aspirin prodrugs:
(i) preparation of N-blocked amino acid and dipeptide caesium salts; (ii) synthesis
of N-blocked amino acid and dipeptide chloromethyl esters; (iii) derivatization of
sulfamethazine and aspirin by reaction with amino acid and dipeptide chloro-
methyl esters.
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EXPERIMENTAL SECTION
Synthesis of the N-Blocked Amino Acid/Dipeptide
Caesium Salts
The appropriate N-blocked amino acid or dipeptide (5mmol) was
suspended in ethanol/water 7:3 v/v (25mL) with magnetic stirring. The
electrode of a pH-meter was dipped into the solution and aqueous
caesium carbonate (1M) was added dropwise until pH 6.5 was reached.
The solvents were then evaporated under low pressure and the resulting
white caesium salt was allowed to dry in vacuum.
Synthesis of the N-Blocked Amino Acid/Dipeptide
Chloromethyl Esters
Bromochloromethane (35mL) was slowly added to a solution of the
appropriate N-blocked amino acid/dipeptide caesium salt (5mmol) in dry
N,N0-dimethylformamide (DMF, 15mL), and the reaction was allowed
to proceed in the dark at room temperature. After 20 h, the caesium
bromide formed was removed by suction filtration and filtrate was
evaporated to dryness. The resulting mixture presented three components
(thin layer chromatography, TLC), by increasing order of Rf, ceasium
bromide, the gem-diester by-product and the main product. This main
product was isolated by low pressure liquid chromatography (LPLC) on
silica, using dichloromethane (DCM)/ethyl ether or DCM/acetone
(in varying proportions) as eluents. Solid compounds were recrystallized
from 1:1 ethyl ether/petroleum ether (40–60) prior to analysis.
The identity and purity of the isolated chloromethyl esters were
checked by 1H and 13CNMR, FAB/Ion Trap or MALDI-TOF MS
and/or elemental analysis.
Synthesis of the N-Blocked Amino Acid/Dipeptide
Sulfamethazine Derivatives
The sodium salt of sulfamethazine (1mmol) was slowly added to a
solution of the appropriate N-blocked amino acid/dipeptide chloromethyl
ester (1mmol) in dry DMF (4mL). The reaction was allowed to proceed
under constant stirring at room temperature, in the dark. After two days,
the mixture was evaporated to dryness and the residue was redissolved
in acetone (2mL) upon heating. The solution was stored at 4C overnight
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to promote the precipitation of sodium chloride, which was then removed
by filtration under reduced pressure. The filtrate was evaporated to dryness
and the resultingmixture revealed the presence of five to seven components
(TLC), the main of which was isolated by LPLC on silica, using
DCM/ethyl ether 1:1 as eluent. Isolated compounds were recrystallized
from 1:1 ethyl ether/petroleum ether (40–60) prior to analysis.
The structure and purity of the isolated compounds were confirmed
by 1H and 13CNMR, MALDI-TOF MS and/or elemental analysis.
Synthesis of the N-Blocked Amino Acid Acetylsalicilic Acid
(‘‘Aspirin’’) Derivatives
The N-blocked amino acid chloromethyl ester (1mmol) was dissolved
in dry DMF (2mL) and acetylsalicilic acid (1mmol) was added.
Triethylamine (1mmol) was then added dropwise. The reaction was
allowed to proceed under constant stirring at room temperature, in the
dark. After three days, the triethylammonium chloride formed was
removed by vacuum filtration and the filtrate was evaporated to dryness.
The residue was redissolved in acetone (2mL) upon heating and left to
stand at 4C overnight for additional precipitation of the triethylammo-
nium salt. After a new cycle of salt filtration and filtrate evaporation to
dryness, the mixture was submitted to LPLC on silica, with ethyl acetate
as eluent. The target product was isolated and characterized by 1H and
13CNMR and by MALDI-TOF MS.
ABBREVIATIONS
Boc, tert-butyloxycarbonyl; DCM, dichloromethane; DMF, N,N0-
dimethylformamide; FAB-MS, fast atom bombardment mass spectrome-
try; LPLC, low pressure liquid chromatography; MALDI–TOF MS,
matrix-assisted laser desorption–time-of-flight mass spectrometry;
NMR, nuclear magnetic resonance; PG, protecting group; TLC, thin
layer chromatography; Z, benzyloxycarbonyl.
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